Population Council

Knowledge Commons

2011

What regulatory guidance exists for multipurpose prevention
technologies (MPTs)? A review of key guidance documents and
their applicability to MPTs
Martha Brady
Population Council

Heeyoung Park

Follow this and additional works at: https://knowledgecommons.popcouncil.org/departments_sbsr-hiv
Part of the Health Policy Commons, Health Services Research Commons, Immune System Diseases
Commons, International Public Health Commons, Medicine and Health Commons, Virus Diseases
Commons, and the Women's Health Commons

How does access to this work benefit you? Let us know!
Recommended Citation
Brady, Martha and Heeyoung Park. 2011. "What regulatory guidance exists for multipurpose prevention
technologies (MPTs)? A review of key guidance documents and their applicability to MPTs." Washington,
DC: Population Council.

This Brief is brought to you for free and open access by the Population Council.

What Regulatory Guidance Exists for Multipurpose
Prevention Technologies (MPTs)? A Review of Key
Guidance Documents and Their Applicability to MPTs
By Martha Brady and Heeyoung Park
Building on its decades of support for developing contraceptives as well as products to prevent sexually transmitted infections (STIs), including HIV, the US Agency for
International Development (USAID) is providing focused
support to facilitate research and development, regulatory approval, and, ultimately, introduction of multipurpose
prevention technologies (MPTs).
As part of this effort, the Population Council is spearheading work to clarify and inform regulatory pathways
for MPTs. These are a unique and specialized subset of
what regulatory authorities, including the US Food and
Drug Administration (FDA), refer to as combination
products. The FDA, 21 CFR 3.2(e), defines combination
products as “a product comprised of two or more regulated components, any combination of a drug, device, and
biological product, produced as a single entity.”

Candidate products undergo review at the FDA
depending on their designation, as follows:
• Drugs: Center for Drug Evaluation and Research
(CDER)
• Biologics: Center for Biologics Evaluation and
Research (CBER)
• Devices and Radioactive Therapy: Center for Devices
and Radiological Health (CDRH)
Jurisdiction for review of combination products is determined by the Office of Combination Products (OCP)
within the FDA, based on a given candidate’s Primary
Mode of Action (PMOA). The PMOA is the single mode of
a combination product that provides the most important
therapeutic action and is expected to make the greatest
contribution to the overall intended effects of the product. The OCP is FDA-wide and makes its determinations
about which sections of the agency to involve on a caseby-case basis depending on the specifics of the proposed
product.1 An important factor in the review of combination
Guidance for Industry and FDA Staff: “How to write a request
of designation (RFD).” www.fda.gov/RegulatoryInformation/
Guidances/ucm126053.htm.
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products is where the drug would fit within existing FDA
structures. Some candidate multi-component drugs could
be reviewed in one division of the FDA, while others may
prompt review in two different divisions.

Review of Existing Guidance
The Population Council conducted a systematic review of
key guidance documents to determine whether and how
they might apply to MPTs for sexual and reproductive
health (SRH). We developed a framework through which
to review these documents, which included four key
areas. We asked whether the guidance:
• Encompasses “combination products”
• Refers to both prevention and therapeutic products
• Considers multi-indication products
• Includes language and discussion of products for SRH
Searching through a broad range of guidance documents
and guidelines from the FDA, European Medicines Agency
(EMA), and International Conference on Harmonization
of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH), we identified four
documents which concern combination drug products,
and thus might prove most relevant to MPTs. We
reviewed the following documents, all of which are in the
public domain and available online:
• FDA/CDER—Guidance for Industry: Co-development of Two or More Unmarketed Investigational
Drugs for Use in Combination (draft Dec. 2010)2
• FDA/OCP—Guidance for Industry and FDA Staff:
Early Development Considerations for Innovative
Combination Products (Sept. 2006)3

www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory
Information/Guidances/UCM236669.pdf
3
www.fda.gov/downloads/RegulatoryInformation/Guidances/
ucm126054.pdf
2

• EMA—Guideline on Clinical Development of Fixed
Combination Medicinal Products (Feb. 2009)4
• ICH—Guidance on Nonclinical Safety Studies for
the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals: M3R2 (June
2009)5

Descriptions of Guidance Documents
Guidance for Industry: Co-development of
Two or More Unmarketed Investigational
Drugs for Use in Combination
This guidance is intended to assist sponsors in the
co-development of two or more novel (not previously
marketed) drugs to be used in combination to treat a
disease or condition. It provides recommendations and
advice on how to address scientific and regulatory issues
that will arise during co-development. The FDA issued
this guidance because the existing developmental and
regulatory paradigm focuses primarily on assessment of
the effectiveness and safety of a single new investigational
drug acting alone, or in combination with an approved
drug. Because co-development will generally provide less
information about the safety and effectiveness of the
individual drugs, it will present greater risk compared
to development of an individual drug. Therefore, the
FDA believes that co-development should ordinarily be
reserved for situations that meet the following criteria:
• The combination is intended to treat a serious disease or condition.
• There is a compelling biological rationale for use of
the combination.
• A preclinical model or short-term clinical study on
an established biomarker suggests that the combination has substantial activity and provides greater than
additive activity or a more durable response compared to the individual agents alone.
• There is a compelling reason for why the agents cannot be developed individually.
The guidance is not intended to apply to development of
fixed-dose combinations of already marketed drugs or
to development of a single new investigational drug to be
used in combination with an approved drug(s). It is also
not intended to apply to vaccines, gene or cellular therapies, blood products, or medical devices.

www.ema.europa.eu/docs/en_GB/document_library/Scientific_
guideline/2009/09/WC500003686.pdf
5
www.ich.org/fileadmin/Public_Web_Site/ICH_Products/
Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf
4
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Guidance for Industry and FDA Staff:
Early Development Considerations for
Innovative Combination Products
This document provides guidance to industry and FDA
staff on developmental considerations for innovative
products that combine devices, drugs, and/or biological
products. It is intended to provide a context for initial
discussions on the type of scientific and technical information that may be necessary for investigational or marketing applications for these combination products. As with
other medical products, combination product development
typically focuses on the scientific and technical issues
raised by the particular product being developed. For a
combination product, these scientific/technical issues will
ordinarily reflect the combination product itself as well
as its constituent parts. When combining products such
as drugs or biologics and devices that are customarily
developed using different regulatory paradigms, certain
critical developmental issues, such as the interaction of the
drug/biologic and device constituents, may not be readily
apparent. Further, because of the breadth, innovation, and
complexity of combination products, there is no single
developmental paradigm appropriate for all combinations.
The FDA recommends that developers consider the scientific and technical issues raised by the combination product
and its constituents, and propose an approach that appropriately addresses these issues without requiring duplicative or redundant studies. When the combination product
is comprised of constituents that are chemically, physically,
or otherwise combined or mixed and produced as a single
entity, developers should consider and, as appropriate,
evaluate the potential for a broad range of drug/biologic/
device interactions. For some combination products, the
constituents may have synergistic effects that should be
evaluated. In the context of these studies, it is appropriate
to discuss approaches to avoid duplication/redundancy and
to develop strategies to streamline the overlapping aspects
of development.

EMA Guideline on Clinical Development of
Fixed Combination Medicinal Products
This guideline provides guidance on the clinical strategy to
be considered when developing fixed combination medicinal products containing two or more active substances,
which can be either well-known or not yet authorized
in the European Union for the intended claim. The
development of fixed combination medicinal products
will reflect the intended use (first- or second-line indication in patients inadequately controlled with individual

component(s) of the combination) and the intended indication (treatment of one disease or, for example, two closely
related diseases, such as hyperlipidemia and hypertension,
or substitution indication). Combination packs would only
be acceptable in exceptional cases, when there would be
clear public health benefits for the treatment regimen and/
or compliance, taking into account the required justifications. Potential advantages and disadvantages of fixed
combinations are also discussed.

ICH Guidance on Nonclinical Safety Studies
for the Conduct of Human Clinical Trials and
Marketing Authorization for Pharmaceuticals
A review of the ICH M3R2, section 17 provides additional
guidance related to preclinical testing for combination
products. Nonclinical toxicity testing is recommended
for combinations. The scope of the nonclinical testing on
individual components is determined by whether those
components are used as single entities (complete testing
required for all individual entities and the combination) or
used in a fixed-dose combination and not individually (only
combination testing required).

Policy Analysis of Guidance:
Application to MPTs for SRH
Our analysis of the existing guidance documents suggests
that while they are generally useful starting points for considering the issues raised by the potential of MPTs, none
of them applies specifically to MPTs for SRH. Further, these
documents focus on therapeutic and single-indication
combination products, not on prevention products per se.
Below we provide a brief policy analysis of each document,
and summarize in Table 1.
The draft FDA guidance on co-development, describing the criteria for determining when co-development is
an appropriate option, makes recommendations about
nonclinical and clinical development strategies, and
addresses certain regulatory process issues. This guidance
excludes fixed-dose combinations of already marketed

drugs or development of a single new investigational drug
to be used in combination with an approved drug(s). And
while this guidance points out that “further new therapeutic approaches using combinations of drugs directed at
multiple therapeutic targets is needed to improve treatment response or minimize development of resistance,”
prevention products and multi-indications are not mentioned in
the document.
The OCP guidance describes general principles to
consider when developing information to demonstrate the
safety and effectiveness of a combination product and its
constituent parts. In the drug constituent considerations
(section V-B), this guidance explains that a new molecular
entity (NME) is a critical consideration in the combination
product. For example, “certain conventional pharmacology
and toxicology studies may be necessary to establish the
safety profile of the NME alone before beginning clinical
investigation of the combination product.” This guidance
focuses on providing considerations and perspectives on
scientific and technical issues in early development of innovative combination products, including drugs, biologics, and
devices. It is quite general, and not specific to prevention drugs
with multiple indications. This guidance makes no mention of
prevention products and multi-indications.
The guideline from the EMA is for fixed-dose combination drug products, which define the combination of
active substances within a single pharmaceutical form of
administration. An example of fixed-dose combination
drugs is multiple antiretrovirals (ARVs) combined into a
single pill, which helps reduce pill burden. These guidelines
mention prevention of disease for selecting doses of each
substance, but the document focuses solely on therapeutics. While this guideline mentions multiple indications, it
limits itself to treatment of one disease or two closely related
diseases: “An indication must be a well-recognized disease
state, or two closely related diseases, or a modification of
a physiological or dysfunctional state, or a syndrome or
pathological entity (section 6.1). The individual substances
of a fixed combination may be intended to relieve simultaneously different symptoms of such a disease state.”

Table 1 Analysis of Application of Existing Guidance to MPTs for SRH
Source of

Includes information on

Refers to both therapeutic

Includes information on

RH issues

guidance

“combination products”?

and prevention products?

multi-indication?

mentioned?

1 - CDER

YES

Therapeutic only

NO

NO

2 - OCP

YES

Therapeutic only

NO

NO

3 - EMA

YES

Both: however prevention is
only mentioned in
dosage proposal

YES, but only for “two closely
related diseases such as hyperglycemia & hypertension….”

NO
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Distilling the Complexity around
Number and Type of Indications

Next Steps

Given the range and diversity of products, the types and
number of ingredients and indications, and the various
FDA designations required for review, we developed a
framework to illustrate and distill this complexity. Table 2
provides a summary of selected products, indications, and
their FDA designation. We have highlighted those which
are already approved by the FDA, and are linked in some
way to SRH (with exception of the combination vaccines). There are a number of multi-indication products in
clinical trials that could potentially be developed as an MPT.

This review and analysis suggests several concrete next
steps. First, we anticipate increased interaction with key
regulatory agencies in the United States and abroad to
help further clarify regulatory issues and challenges. Second, drawing upon knowledge and experience in the area
of combination products, along with work around accelerated pathways, we will work with key individuals and institutions to develop a road map for regulatory pathways for
MPTs. Finally, we hope this effort to understand and clarify
regulatory processes will help the emerging field of MPTs.

Table 2 Product, Number and Type of Indication, and FDA Designation: Selected Examples
Number of

Number of

Product name

Indication(s)

ingredients

indications

Single product
Single product

Single

Copper T IUD

Pregnancy prevention

CDER

Multiple

Mirena® IUS

Pregnancy prevention, Rx heavy bleeding

CDER

Pitocin

Induce uterine contraction; prevention of postpartum
hemorrhage

CDER

Cytotec®

Prevention of gastric ulcer; induce uterine contraction

CDER

Condom

Pregnancy prevention, reduce STIs

CDRH

Combined ARVs

HIV treatment; partial prevention of HIV

CDER

Combined OCs

Pregnancy prevention

CDER

IPOL®

Prevention of polio

CBER

Flu vaccines

Prevention of influenza

CBER

Prevention of invasive S. pneumoniae diseases

CBER

Prevention of HPV induced cervical, vulvar and rectal
cancers, and genital warts

CBER

DPT

Prevention of diphtheria, tetanus, and pertussis (DTP)

CBER

MMR

Prevention of measles, mumps, and rubella

CBER

PEDIARIX®

Prevention of polio, hepatitis B, and DTP

CBER

Pentacel

Prevention of polio, DTP, and invasive Haemophilus
influenzae type b disease

CBER

designation

®

Multi-ingredient

Single

FDA

Multi-valent vaccines

Multi-ingredient

Multiple

Multi-valent vaccines
Prevnar®
Gardasil /Cervarix
®

Multi-product

Mutliple

®

Combination vaccines

®
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